Avoidable Costs in Patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Treated with Darolutamide

Speaker(s)

Roa M1, López-Cabra C1, Torres L1, Salcedo Mejía F2, Camerano R3, Chaparro Vivanco FA2, Fernandez Mercado J4, Gómez De la Rosa F5, Alvis Zakzuk NR6, Alvis-Guzman N7, Marrugo R1
1Bayer, Bogotá, CUN, Colombia, 2ALZAK, Cartagena, Bolívar, Colombia, 3ALZAK, Bogotá, CUN, Colombia, 4Secretaria de Salud Bolivar Colombia -University of Cartagena, Cartagena, BOL, Colombia, 5ALZAK, Cartagena, BOL, Colombia, 6ALZAK Foundation, Cartagena, Bolivar, Colombia - Institucion Universitaria Mayor de Cartagena, Cartagena, Bolívar, Colombia, 7Universidad De La Costa, Cartagena, BOL, Colombia

OBJECTIVES: To describe the potential impact of darolutamide avoidable costs (those related to symptomatic skeletal event-SSE, avoidable fractures, radiotherapy, hospitalization among other procedures or interventions associated to progression) in patients with mHSPC affiliated to a health insurance company, treated in a regional reference center in Colombia.

METHODS: Using efficacy parameters extracted from ARASENS clinical trial indicating a lower risk (-64%) for progression to castration-resistant metastatic cancer (mCRPC) for darolutamide users. Thus, based on direct medical costs in patients with metastatic Hormone Sensitive Prostate Cancer (mHSPC) in Colombia, we developed an economic model to estimate avoidable costs due to progression to mCRPC. A Monte Carlo simulation of 1,000 repetitions is carried out where intervention with darolutamide and the control group were randomized in mHSPC. The total accumulated cost was estimated during a 4 years period time using the progression-free probabilities from the ARASENS study

RESULTS: Considering the costs of the 127 hormone-sensitive patients with mHSPC, thus simulating costs avoided by progression/delay to a metastatic state resistant to castration. Patients who received darolutamide would have cumulative median costs[1] of US$ 673,114 (CI95% US$539,580 - US$816,267). On the other hand, those who did not receive the treatment had average accumulated costs of US$1.043.924 (95% CI US$849.533 - US$1.221.446). Hence, the use of darolutamide in patients with mHSPC, implies a reduction of 35.5% (95% CI -51.9%; - 24.0%) of the cumulative costs.

[1] An exchange rate of COP$3,932.59 Colombian per US dollar (USD), was used.

CONCLUSIONS: Darolutamide-treated group shows lower annual costs than best supportive care (BSC) patient group, due to a lower risk of progression to mCRPC state, implying an important set of health expenditure that could be avoided/delayed.

Code

EE168

Topic

Economic Evaluation

Topic Subcategory

Cost-comparison, Effectiveness, Utility, Benefit Analysis

Disease

Oncology